GlassScriptPhysician profile
Robert F Dodge
NPI 1508910589
$1,871.08
in general payments reported to CMS, 2019-2025
23 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $60.68 · 2021: $114 · 2022: $218 · 2023: $467 · 2024: $515 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $438.19 | 2023-2025 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $297.22 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $183.17 | 2022-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $137.92 | 2023-2024 | Rexulti |
| Abbott Laboratories | $114.30 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3, Proclaim |
| Glaxosmithkline, LLC. | $102.02 | 2022-2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $88.45 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $87.38 | 2021-2024 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.97 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $44.95 | 2021-2022 | |
| Edwards Lifesciences Corporation | $44.65 | 2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $44.30 | 2023-2025 | Farxiga |
| Phadia US INC. | $36.87 | 2021-2022 | |
| Bioventus LLC | $30.34 | 2021 | |
| Sanofi Pasteur INC. | $23.81 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $20.73 | 2025 | Qelbree |
| Boston Scientific Corporation | $20.72 | 2023 | |
| Organon LLC | $19.93 | 2022 | |
| Cranial Technologies, INC | $19.05 | 2024 | Doc Band |
| Merck Sharp & Dohme LLC | $18.25 | 2024 | M-M-R II, Varivax, Gardasil |
| Microtransponder, INC. | $17.41 | 2023 | |
| Nevro Corp. | $16.53 | 2023 | Senza |
| Almatica Pharma LLC | $13.92 | 2023 | Loreev Xr, Gralise, Sertraline Hcl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dodge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.